Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Bullous Pemphigoid in Adults (Japan Phase 2-3)
jRCT2080225313Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Dupilumab arm with Placebo arm (2 arms). Primary endpoint: Efficacy at week 36. Started Aug 2020; status: completed.
02
Drugs
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on jRCT2080225313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225313.